Karuna Therapeutics set to merge with Bristol-Myers Squibb By Investing.com

Published on 14 Mar 2024 on Investing.com

The waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976 (HSR Act), which is...

Read the rest of the article

Start tracking your investments with Statfolio

Bristol Myers Squibb (BMS) has successfully completed its acquisition of Karuna Therapeutics, Inc...

New Jersey Business Magazine 18 Mar 2024

With the business potentially at an important milestone, we thought we'd take a closer look at Ka...

Simply Wall St. via Yahoo Finance 15 Mar 2024

The waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976 (HSR Act), which...

Investing.com 14 Mar 2024

Karuna Therapeutics Inc (NASDAQ:KRTX), a clinical-stage biopharmaceutical company focused on deve...

GuruFocus.com via Yahoo Finance 11 Mar 2024

Karuna Therapeutics, Inc. KRTX reported a loss of $3.01 per share in fourth-quarter 2023, wider t...

Zacks via Yahoo Finance 23 Feb 2024

Strengths: Innovative CNS-focused pipeline with lead candidate KarXT showing promise in clinical ...

GuruFocus.com via Yahoo Finance 23 Feb 2024

(Bloomberg) -- Pharmaceutical giant AbbVie Inc. is looking to sell at least $13 billion of corpor...

Bloomberg via Yahoo Finance 21 Feb 2024

(Bloomberg) -- Fears of a systemic credit event are growing among fund managers as alarms sound i...

Bloomberg via Yahoo Finance 17 Feb 2024

RBC Capital Markets has initiated Biohaven Ltd BHVN, noting optimized development across programs...

Benzinga 16 Feb 2024

(Bloomberg) -- A renewed wave of dip buying sent stocks and bonds higher, following a slide trigg...

Bloomberg via Yahoo Finance 14 Feb 2024